Abstract
To estimate health care resource utilization (HRCU) and costs in different disease stages of acute myeloid leukemia (AML) in Finland. Real world data of adult patients (≥18 years) diagnosed with AML (ICD-10 C92.0) 2004-2016 was collected from Auria Biobank. Data on HCRU (secondary healthcare visits, medical procedures, laboratory tests, AML-related hospital drugs) were collected from the medical records of Turku university hospital. The unit costs were extracted from the 2020 hospital price list. Drug costs are not included in the cost calculation. Costs are reported as average cost per patient. A total of 191 diagnosed patients (56% men) were identified. FLT3-mutation status was available from 120 patients, including 23 cases (19%) of FLT3-ITD and 5 cases (4%) of FLT3-TKD mutations. 119 patients (62%) received standard intensive chemotherapy, with 71% reaching complete remission (CR) after the 1st induction. Allogenic stem cell transplantation (SCT) was given to 57 patients (30%), out of which 33% were later diagnosed with graft versus host disease. The costs of induction (1st month of follow-up) were 32,605€, consolidation (1st month from the beginning of consolidation phase) 26,829€, CR after consolidation (6th-7th month of the follow-up) 4,500€, post relapse (1st month after relapse) 20,877€, pre SCT (1st month before the operation) 37,400€, post SCT (2 years after the operation) 57,044€ and one month before death 10,208€. The cost of treatments of first year after relapse was 102,272€. Hospitalization, outpatient visits, blood transfusions, bone marrow biopsies and laboratory tests accounted for 81%, 7%, 6%, 1% and 5% of the costs respectively. First month and first three months accounted for 21% and 46% of the costs. Majority of the costs accrued during induction therapy, pre and post SCT. It’s noteworthy that the treatment duration for which the costs are reported varies between the different disease stages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
